APA (7th ed.) Citation

Catlett, I. M., Gao, L., Hu, Y., Banerjee, S., & Krueger, J. G. (2024). Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial. Dermatology & Therapy, 14(10), 2827. https://doi.org/10.1007/s13555-024-01262-5

Chicago Style (17th ed.) Citation

Catlett, Ian M., Lu Gao, Yanhua Hu, Subhashis Banerjee, and James G. Krueger. "Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial." Dermatology & Therapy 14, no. 10 (2024): 2827. https://doi.org/10.1007/s13555-024-01262-5.

MLA (9th ed.) Citation

Catlett, Ian M., et al. "Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial." Dermatology & Therapy, vol. 14, no. 10, 2024, p. 2827, https://doi.org/10.1007/s13555-024-01262-5.